Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Steve Cohen’s Point72 Bullish On Olin Corporation (OLN) & Raises Stake To 6.4%

Page 1 of 2

In a newly-amended filing with U.S. Securities and Exchange Commission, Steve Cohen’s Point72 Asset Management disclosed increasing its position in Olin Corporation (NYSE:OLN), as it is about to complete its merger with Dow Chemical Co (NYSE:DOW). The investor raised his position in Olin Corporation (NYSE:OLN) to over 4.94 million shares from 4.06 million shares held previously, according to the filing. Point72’s current stake is equal to 6.4% of Olin Corporation (NYSE:OLN)’s outstanding common stock.


Based in Connecticut, Point72 Asset Management is the legal successor of the hedge fund SAC Capital Advisors. It was launched in April 2014 with approximately $9 billion in initial capital, which represented Mr. Cohen’s personal wealth. SAC Capital was shut down in 2013 and paid a substantial fine to settle insider-trading charges. Point72 Asset Management, is prohibited from managing money for outside investors as part of the settlement with the Department of Justice. Point72 employs a long/short equity investing approach and makes significant quantitative and macro investments. According to the fund’s latest 13F filing with the SEC, Point72 manages an equity portfolio worth $14.67 billion as of March 31.

Steve Cohen
Steve Cohen
Point72 Asset Management

Tracking hedge funds and prominent investors like Steve Cohen is a wise decision because our research has shown that historically their stock picks delivered superior risk-adjusted returns. This is especially true in the small-cap space. The 50 most popular large-cap stocks among hedge funds had a monthly alpha of about 6 basis points per month between 1999 and 2012; however the 15 most popular small-cap stocks delivered a monthly alpha of 80 basis points during the same period. This means investors would have generated 10 percentage points of alpha per year simply by imitating hedge funds’ top 15 small-cap ideas. We have been tracking the performance of these stocks since the end of August 2012 and these stocks beat the market by 84 percentage points (135% return vs. S&P 500’s 55% gain) over the last 34 months (see the details here).

Point72 stated in the filing that it acquired shares of Olin Corporation (NYSE:OLN) for investment purposes and it has no intentions to influence the control or management of the company.

Olin Corporation (NYSE:OLN) is a manufacturing company, with a market cap of $1.96-billion. It operates three business segments: Chlor Alkali Products, Chemical Distribution and Winchester. Last week, Olin Corporation (NYSE:OLN) reported that it received all the foreign regulatory approvals required to close its pending merger with Dow Chemical Co (NYSE:DOW). Under the agreement, Olin Corporation (NYSE:OLN) has agreed to buy certain chlor alkali and downstream derivatives businesses from Dow using a Reverse Morris Trust structure. As part of the deal, Dow will first transfer its U.S. chlor alkali and vinyl, global chlorinated organics, and global epoxy businesses to a subsidiary. Next, the company will distribute the stock of that subsidiary to its shareholders through a split-off or spin-off or a combination. Then, the subsidiary will immediately merge with Olin.

What will Dow’s shareholders get from this deal? You can read it on the next page.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!